Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $5.6752W HIGH $21.98
Volume
54.50 K
Value Traded
7.41 K
Short % Float
3.88%
-9.14%Week
-13.46%1 Month
-14.81%3 Month
-19.11%6 Month
-97.8%5 Year
-98.49%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
44.49 M
EPS (TTM)
-4.46
P/E Ratio
-
Ent. Value
-25.19 M
Total Shares
6.78 M
Float Shares
4.17 M
Insiders
38.58%
Institutions
28.35%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
TIL Catalyst Timeline
Dated clinical, regulatory and corporate events for Instil Bio, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Instil Bio, Inc.
190Total events
2Upcoming
30Tier-1 (high impact)
2021 to 2026Coverage
Upcoming catalysts 2
Event history 50
◆Trial InitiationIMM2510Trial
Phase 3 trial of '2510 in combination with chemotherapy in first-line NSCLC anticipated to start in mid-2026 in China
first-line NSCLCsource ↗
●Runway Guidance UpdateCorporate
Cash position of $74.7M expected to fund operating plan beyond 2027
▲Runway Guidance UpdateCorporate
Cash position of $76.3M expected to fund operations beyond 2027
▼Program DiscontinuationAXN-2510DiscontinuedCorporate
Discontinuation of clinical development of AXN-2510
▼Partnership / LicenseAXN-2510DiscontinuedCorporate
Termination of license and collaboration agreement for AXN-2510 and AXN-27M
▼Program DiscontinuationAXN-2510DiscontinuedCorporate
Discontinued clinical development of AXN-2510
▼Partnership / LicenseAXN-2510DiscontinuedCorporate
Terminated license and collaboration agreement for AXN-2510 and AXN-27M
▲Runway Guidance UpdateCorporate
Cash runway expected into 2025 upon sale-leaseback of Tarzana facility
▲Runway Guidance UpdateCorporate
Cash runway guidance: expects to fund operations beyond 2026
◆Oral Presentation2510Presentation
ImmuneOnco presented preliminary efficacy and safety data of '2510 monotherapy in 2L+ sq-NSCLC at WCLC 2025
squamous non-small cell lung cancersource ↗
◆Poster PresentationAXN-2510DiscontinuedPresentation
Updated monotherapy data in squamous-NSCLC to be presented at WCLC 2025
squamous-NSCLCsource ↗
▲Topline ReadoutIMM2510Clinical Data
Preliminary safety and efficacy data from Phase 2 study of IMM2510/AXN-2510 in combination with chemotherapy in front-line NSCLC
front-line non-small cell lung cancer (NSCLC)source ↗
▲IND ClearanceAXN-2510DiscontinuedIND
FDA clearance of IND for AXN-2510
relapsed/refractory solid tumorssource ↗
◆Enrollment CompleteAXN-2510DiscontinuedTrial
Completion of enrollment of Phase 2 trial of AXN-2510 in combination with chemotherapy in first-line NSCLC
first-line non-small cell lung cancersource ↗
◆Topline ReadoutAXN-2510DiscontinuedClinical Data
Initial clinical data for AXN-2510/IMM2510 + chemo in 1L NSCLC in China expected in 2H 2025
first-line non-small cell lung cancersource ↗
◆Enrollment CompleteIMM2510Trial
Phase 2 trial of '2510 in combination with chemotherapy in first-line NSCLC on track to complete enrollment in Q3 2025
first-line NSCLCsource ↗
◆Topline ReadoutIMM2510Clinical Data
Initial clinical data from 1L advanced NSCLC trial expected as early as 2H 2025
first-line advanced non-small cell lung cancer (NSCLC)source ↗
◆Trial InitiationSYN-2510Trial
Instil targets initiation of U.S. clinical trial of SYN-2510/IMM2510 plus chemotherapy in 1L NSCLC in 2H 2025
first-line advanced non-small cell lung cancer (NSCLC)source ↗
▲Trial InitiationSYN-2510Trial
U.S. clinical study of SYN-2510 in NSCLC initiation targeted
non-small cell lung cancersource ↗
◆Management ChangeCorporate
Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
◆Enrollment UpdateAXN-2510DiscontinuedTrial
Enrollment ongoing in China trial of AXN-2510/IMM2510 in combination with chemotherapy in 1L NSCLC
1L NSCLCsource ↗
◆Enrollment UpdateAXN-2510DiscontinuedTrial
Enrollment of 1L NSCLC patients in Phase 1b/2 trial of AXN-2510/IMM2510 + chemo in China anticipated to begin in Q2 2025
first-line non-small cell lung cancersource ↗
▲First Patient DosedIMM2510Trial
First patient dosed in Phase 1b/2 trial of IMM2510/SYN-2510 plus chemotherapy in advanced NSCLC in China
advanced non-small cell lung cancer (NSCLC)source ↗
▲Trial InitiationAXN-2510DiscontinuedTrial
Initiation of US Phase 1 clinical trial of AXN-2510
multiple solid tumorssource ↗
◆Trial InitiationAXN-2510DiscontinuedTrial
Initiation of U.S. clinical study of AXN-2510/IMM2510 + chemo in 1L NSCLC anticipated before end of 2025
first-line non-small cell lung cancersource ↗
◆Trial InitiationSYN-2510Trial
Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line TNBC in China
first-line triple-negative breast cancersource ↗
◆Trial InitiationIMM2510Trial
Monotherapy US dose optimization Phase 1b/2 trial of '2510 in relapsed/refractory solid tumors to start later this year
relapsed/refractory solid tumorssource ↗
◆Topline ReadoutAXN-2510DiscontinuedClinical Data
Clinical data for AXN-2510/IMM2510 monotherapy in R/R NSCLC anticipated in 1H 2025
relapsed/refractory non-small cell lung cancersource ↗
◆Safety Data UpdateAXN-2510DiscontinuedClinical Data
Safety data from ~100 patients treated with AXN-2510/IMM2510 monotherapy across multiple solid tumors anticipated in 1H 2025
solid tumorssource ↗
▲First Patient DosedAXN-2510DiscontinuedTrial
First patient dosed in safety run-in of Phase 1b/2 trial of AXN-2510/IMM2510 + chemo in NSCLC in China
non-small cell lung cancersource ↗
◆Topline ReadoutSYN-2510Clinical Data
Clinical data update for SYN-2510/IMM2510 monotherapy in China
multiple solid tumorssource ↗
▲Runway Guidance UpdateCorporate
Cash runway into 2025 upon successful completion of potential sale-leaseback
◆Full ResultsSYN-27MClinical Data
Initial clinical results for SYN-27M/IMM27M in ER+ advanced breast cancer
ER+ advanced breast cancersource ↗
▲Trial InitiationSYN-27MTrial
Initiation of Phase 2 clinical trial of SYN-27M/IMM27M for ER+ breast cancer
ER+ breast cancersource ↗
◆Trial InitiationSYN-2510Trial
Initiation of Phase 1b/2 IMM2510/SYN-2510 + chemotherapy combination in first-line NSCLC in China
first-line non-squamous and squamous non-small cell lung cancersource ↗
●IND SubmissionSYN-2510IND
US IND submission for SYN-2510 targeted in late 2024
second-line non-squamous and squamous non-small cell lung cancersource ↗
▲Partnership / LicenseIMM2510Corporate
Instil Bio in-licenses ex-China rights to IMM2510 from ImmuneOnco
advanced solid tumorssource ↗
▲Partnership / LicenseIMM27MCorporate
Instil Bio in-licenses ex-China rights to IMM27M from ImmuneOnco
advanced solid tumorssource ↗
Past FDA Catalysts and PDUFA Decisions
How TIL actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | SYN-2510 (PD-L1xVEGF bispecific antibody) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
Clinical Trial Results
Readouts, endpoints and source filings for every TIL program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| '2510 | squamous non-small cell lung cancer | Phase 1 | 2025-09-10 | In a Phase 1 trial, ‘2510 demonstrated an objective response rate (ORR) of 35.3% in 17 evaluable patients with previously treated squamous non-small cell lung cancer, with the majority of responses occurring in patients with negative and low PD-L1 TPS scores.Read More | Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Laumas SandeepOfficer (CFO and CBO) | Option | 17,000 17,000 held | $11.60 | 09/10/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in TIL
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Vivo Capital, LLC | 0.2 % | 2.25 M | 292.74 K |
TIL Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How TIL ranks across every disease it competes in
Competitive Position is a premium feature
See how TIL ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialTIL News
TILInstil Bio Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio, a biotechnology company, has announced its financial results for the second quarter of 2026. The report highlights the company's ongoing commitment to developing innovative therapeutics. This update reflects Instil's progress and future direction in the biopharmaceutical sector.
Read more →TILInstil Bio Reports First Quarter 2026 Financial Results and Provides Corporate Update
Instil Bio reported its Q1 2026 financial results, highlighting a cash position of $74.7 million, which is expected to fund operations beyond 2027. The company is exploring acquisitions and in-licensing opportunities to enhance its therapeutic pipeline. While expenses have decreased, the net loss per share remains a concern despite improvements from the previous year.
Read more →TIL▼ -5.5%on this news
Instil Bio, Inc. Investigated by the Portnoy Law Firm
Instil Bio, Inc. is under investigation by the Portnoy Law Firm for possible securities fraud, following a drastic drop in stock price. The company's shares plummeted 45.81% after announcing the discontinuation of significant drug development programs and the termination of a collaboration agreement with ImmuneOnco Biopharmaceuticals. This has raised alarms among investors about the financial stability and future prospects of Instil. The firm is promoting the opportunity for affected investors to pursue legal actions to recover losses.
Read more →TIL▼ -6.8%on this news
Instil Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its fourth quarter and full year 2025 financial results, highlighting a cash position of $76.3 million. The company plans to focus on strategic development through potential acquisitions and in-licensing opportunities. However, it discontinued clinical development of AXN-2510, indicating a shift in its operational strategy. Despite a significant net loss, management remains optimistic about future value creation.
Read more →TIL▼ -45.8%on this news
Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco
Instil Bio's subsidiary, Axion Bio, has halted the clinical development of AXN-2510 and terminated its license and collaboration agreement with ImmuneOnco Biopharmaceuticals. As a result, all global development and commercial rights outside Greater China have reverted to ImmuneOnco. Axion retains a limited license to wind down clinical activities, but the decision signals significant setbacks for Instil Bio's portfolio. The company may also face broader risks related to regulatory processes and macroeconomic factors.
Read more →TIL▼ -7.2%on this news
Instil Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its third quarter 2025 financial results, showing a cash position of $83.4 million, which is expected to fund operations beyond 2026. The company experienced a decrease in net loss per share compared to the previous year, while research and development expenses rose significantly. However, restructuring charges increased, and total cash and marketable securities decreased from the prior year.
Read more →TIL▼ -9.8%on this news
Instil Bio Announces ImmuneOnco’s Presentation of ‘2510 Monotherapy Data in Patients with 2L+ Squamous NSCLC at the 2025 World Conference on Lung Cancer (WCLC)
Instil Bio announced promising preliminary data for its bispecific antibody, '2510', presented by ImmuneOnco at the 2025 World Conference on Lung Cancer. The Phase 1 study showed a 35.3% objective response rate in patients with previously treated squamous non-small cell lung cancer. The treatment was generally well tolerated, although two serious adverse events were noted. Enrollment continues at the highest dose level.
Read more →TILInstil Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio, Inc. reported its second quarter 2025 financial results, revealing a cash position of $103.6 million, sufficient to support operations beyond 2026. A significant milestone includes the clearance of the Investigational New Drug application for the AXN-2510 therapy, with a clinical trial anticipated before the end of 2025. The company will also present new data at the upcoming IASLC World Conference on Lung Cancer, signaling progress in their clinical programs. However, the company recorded an increase in net losses and faced restructuring charges during this period.
Read more →TIL▼ -11.1%on this news
ImmuneOnco Announced Preliminary Safety & Efficacy Data from the Clinical Trial Studying IMM2510/AXN-2510, a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in Front-line NSCLC in China
ImmuneOnco Biopharmaceuticals announced preliminary results from a Phase 2 study of IMM2510/AXN-2510 in combination with chemotherapy for front-line NSCLC in China. The study showed an 80% partial response rate in squamous patients and 46% in non-squamous patients, with a favorable safety profile. Further data will be presented at a future conference, and the company plans to advance to Phase 3 trials.
Read more →TIL▲ +8.6%on this news· ran to +25% by day 1
Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
Instil Bio has received FDA clearance for its Investigational New Drug application for AXN-2510, a bispecific antibody targeting PD-L1 and VEGF. The company plans to initiate a Phase 1 trial for relapsed/refractory solid tumors before the end of 2025. Initial results from a Phase 2 trial in combination with chemotherapy are anticipated in the second half of 2025.
Read more →TILInstil Bio Names John Maraganore, Ph.D., to Board Role Supporting the Advancement of PD-L1xVEGF Bispecific Antibody Program
Instil Bio has appointed Dr. John Maraganore to its Board of Directors to enhance the development of AXN-2510, a PD-L1xVEGF bispecific antibody targeting solid tumors, particularly non-small cell lung cancer. Dr. Maraganore's extensive experience in biotechnology is expected to guide the program's advancement as it approaches the completion of its Phase 2 trial. His strategic insights are viewed as critical for maximizing the program's value.
Read more →TIL▲ +10%on this news
Instil Bio Announces Appointment of Jamie Freedman, M.D., Ph.D., as Chief Medical Officer
Instil Bio has appointed Dr. Jamie Freedman as Chief Medical Officer, bringing over 20 years of experience in oncology drug development. Dr. Freedman aims to advance the development of AXN-2510, a promising bispecific antibody targeting solid tumors. His extensive background includes leadership roles at major pharmaceutical companies and a commitment to health equity.
Read more →TIL▼ -11.2%on this newsshared move
Instil Bio to Participate in the 2025 Jefferies Global Healthcare Conference
Instil Bio, a clinical-stage biopharmaceutical company, announced its participation in the 2025 Jefferies Global Healthcare Conference. CEO Bronson Crouch will present on June 5, 2025, at 4:20 PM ET. The company is known for its lead asset, AXN-2510, a bispecific antibody targeting multiple solid tumors. A live webcast of the presentation will be available.
Read more →TIL▼ -14.6%on this news
Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago
Instil Bio and ImmuneOnco will host an investor and analyst breakfast on May 31, 2025, in Chicago. The event aims to discuss the evolving landscape of PD-(L)1xVEGF bispecific antibodies and share recent clinical trial updates. Attendees are encouraged to register in advance to secure their seats.
Read more →TIL▲ +51.7%on this news· ran to +65% by day 3shared move
Instil Bio and ImmuneOnco Announced the Phase 2 Trial in First-line NSCLC of IMM2510/AXN-2510 (‘2510), a PD-L1xVEGF Bispecific Antibody, in Combination with Chemotherapy in China is on Track to Complete Enrollment in Q3 2025; Initial Results Anticipated in 2H 2025
Instil Bio and ImmuneOnco have announced that the Phase 2 trial of IMM2510 in combination with chemotherapy for first-line NSCLC is on track for enrollment completion by Q3 2025, with initial results expected in the second half of 2025. The companies are also preparing for a Phase 3 trial anticipated to start in mid-2026, pending regulatory discussions. The collaboration aims to leverage the bispecific antibody's potential in treating multiple solid tumors.
Read more →TIL▼ -6.9%on this news
Instil Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
Instil Bio reported its first-quarter financial results for 2025, highlighting ongoing enrollment in clinical trials for its lead asset AXN-2510 in first-line non-small cell lung cancer (NSCLC). The company has significant cash reserves that will fund operations into 2026 and is preparing to initiate a U.S. clinical study for the asset by the end of 2025, contingent on regulatory approvals. However, the company experienced a substantial rise in restructuring charges and an increase in net loss per share compared to the same period last year, which may prompt scrutiny from investors.
Read more →TILInstil Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Instil Bio has reported its fourth quarter and full year 2024 financial results, revealing a significant cash position of $115.1 million. The company anticipates clinical data updates for its drug AXN-2510/IMM2510 in relapsed/refractory NSCLC in the first half of 2025 and plans to begin enrolling patients for a trial in China in Q2 2025. A U.S. study is also expected to start before the end of 2025, contingent on regulatory approval. Despite positive developments, the company continues to face financial losses and regulatory uncertainties.
Read more →TIL▲ +5.3%on this news
Instil Bio Announces Clinical Progress in China for IMM2510/SYN-2510, a Clinical-Stage PD-L1xVEGF Bispecific Antibody
Instil Bio announced progress regarding its IMM2510/SYN-2510 bispecific antibody in collaboration with ImmuneOnco in China. The Phase 1b/2 trial has commenced, with the first patient enrolled in a study targeting advanced non-small cell lung cancer (NSCLC) combined with chemotherapy. Initial clinical data from this trial is projected to be available in the second half of 2025, which may influence further global studies. Simultaneously, Instil expects to initiate its own U.S. trial for the same indication, pending regulatory approvals.
Read more →TIL▼ -5.5%on this news· ran to -25% by day 3
Instil Bio Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Instil Bio reported its third quarter 2024 financial results, revealing a strategic licensing agreement for SYN-2510, a PD-L1xVEGF bispecific antibody. The company anticipates clinical updates in 2025 and is initiating multiple studies for SYN-2510 in both China and the U.S. Financially, Instil holds $122.9 million in cash and securities, expected to support operations past 2026. Despite positive developments, the company continues to face significant net losses.
Read more →TIL▼ -23.9%on this news
Instil Bio and ImmuneOnco Announce Global Registrational Strategy for PD-L1xVEGF Bispecific Antibody, SYN-2510/IMM2510, in Non-Small Cell Lung Cancer and Triple-Negative Breast Cancer
Instil Bio and ImmuneOnco have announced a global registrational strategy for their PD-L1xVEGF bispecific antibody, SYN-2510/IMM2510, targeting non-small cell lung cancer (NSCLC) and triple-negative breast cancer (TNBC). Phase 1b/2 trials in China are set to begin in late 2024 for NSCLC and early 2025 for TNBC. An IND submission for SYN-2510 in the US is planned for late 2024, focusing on a Phase 2 trial in second-line NSCLC. The companies aim to address significant unmet medical needs in these cancers with their innovative treatment approach.
Read more →About Instil Bio, Inc.
Headquarters3963 MAPLE AVENUE, DALLAS, TX, 75219
BIOPHARMAWATCH ELITE PLUS
Trade the next TIL catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime